Correspondence 0001104659-24-079975 from ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC.
Date: July 15, 2024 · CIK: 0001652935 · Accession: 0001104659-24-079975
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279734
Letter
Actuate Therapeutics, Inc.
1751 River Run, Suite 400
Fort Worth, TX 76107
July 15, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Eric Attalah, Kevin Kuhar, Jessica Dickerson and Tim Buchmiller
Re: Actuate Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-279734
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Actuate Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 17, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
We request that we be notified of such effectiveness by a telephone call to Janet Spreen of Baker & Hostetler LLP, counsel to the Company, at (216) 861-7564 and that such effectiveness also be confirmed in writing.
Very truly yours,
Actuate Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Actuate Therapeutics, Inc.
1751 River Run, Suite 400
Fort Worth, TX 76107
July 15, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Eric Attalah, Kevin Kuhar, Jessica Dickerson
and Tim Buchmiller
Re: Actuate Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-279734
Ladies and Gentlemen:
Pursuant to Rule 461 under
the Securities Act of 1933, as amended (the “Act”), Actuate Therapeutics, Inc. (the “Company”) hereby
requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated
to July 17, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler
LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request,
the Company acknowledges that it is aware of its obligations under the Act.
We request that we be notified
of such effectiveness by a telephone call to Janet Spreen of Baker & Hostetler LLP, counsel to the Company, at (216) 861-7564 and
that such effectiveness also be confirmed in writing.
Very truly yours,
Actuate Therapeutics, Inc.
By:
/s/ Daniel M. Schmitt
Daniel M. Schmitt
President and Chief Executive Officer